Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.

Slides:



Advertisements
Similar presentations
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ Multiple Myeloma: Is FISH passé? Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Treatment For Newly Diagnosed Myeloma
Should Alkylators be used Upfront in Transplant-Ineligible Patients? NO!! Lymphoma-Myeloma October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Richardson PG et al. Proc ASH 2013;Abstract 535.
Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Pomalidomide, Bortezomib.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Optimal Use of Newly Approved Agents – Carfilzomib and Pomalidomide Lymphoma-Myeloma Symposium October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Novel Therapies for Myeloma A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Disclosure of Potential Conflicts of Interest.
Relapsed and Refractory Myeloma Case 2
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Multiple Myeloma Update from the American Society of Clinical Oncology (ASCO) 43 rd Annual Meeting Welcome and Introduction Nikhil Munshi, MD Dana-Farber.
Relapsed and Refractory Myeloma Case 1 James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple.
Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.
Morie Gertz Chair Dept. of Medicine
IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM New Findings in Hematology: Independent.
A Phase I/II Trial of Bendamustine and Pomalidomide with Dexamethasone (BPd) in Patients with Relapsed/Refractory Multiple Myeloma Duke University Cristina.
Reeder CB et al. ASCO 2009; Abstract (Poster)
Korde N et al. Proc ASH 2012;Abstract 732.
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma CCO Independent Conference Highlights of the 2015 ASCO Annual.
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Treatment of Immunoglobulin Light Chain Amyloidosis
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Challenging Cases in Multiple Myeloma Panel Discussion
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.
Multiple Myeloma: Diagnosis and Treatment
Multiple Myeloma:2013 Update Genomies
Therapy for Relapsed Multiple Myeloma
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization  Ivana N.M. Micallef,
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ Of the following frontline options for transplant-ineligible MM, which would you recommend?
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Zaja F et al. Proc ASH 2010;Abstract 966.
Therapy for Relapsed Multiple Myeloma
Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines  Stephen.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,
Maintenance therapies in Multiple Myeloma
Presentation transcript:

Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory disease? Novel doublets ± corticosteroids Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center

Disclosures Consulting: AMGEN, Genzyme, BMS, Otsuka, Celgene, Medtronic, Lilly, Millennium, Binding Site, Onyx, Bayer Speakers Bureaus: None Research: Cylene, Proteolix Patent for FISH based prognostication in MM - about $1500 per year Registered independent Believe in stem cell transplant Dislike wasting your time with this slide

POM-V-D 1-4 lines of Rx (median 2) Refractory to lenalidomide (67% progressed as last Rx) Not to bortezomib >= 2 cycles bortezomib 28 pts enrolled, 20 evaluable for response Bortezomib d 1, 4, 8, &11 1 & 8 after cycle 8

POM-V-D MTD pomalidomide 4 mg and bortezomib 1.3 mg/m2 ORR is 75% 30% VGPR or better One sCR TTR is 1 month Need larger randomized trials

A Phase I/II Trial of Pomalidomide, Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Joseph Mikhael MD1, Vivek Roy2, MD; Paul Richardson MD3; Andrzej Jakubowiak, MD4; Kristina Laumann5, Betsy LaPlant5; Angela Dispenzieri, MD5; S. Vincent Rajkumar, MD5; Rafael Fonseca, MD1; Nelson Leung, MD5; Francis K. Buadi, MD5, P. Leif Bergsagel; MD1, Robert A. Kyle, MD5; Thomas E. Witzig, MD5; Craig B. Reeder, MD; John A. Lust, MD, PhD5; Stephen J. Russell, MD, PhD5; Suzanne R. Hayman, MD5; Shaji Kumar, MD5; David Dingli, MD, PhD5; Stephen M. Ansell, MD, PhD5, Robert J. Dalton, MD5; Yi Lin, MD, PhD5, Taimur Sher, MD2, Prashant Kapoor, MD5, Arleigh McCurdy, MD5; Asher Chanan-Khan, MD2, A. Keith Stewart, MBCHB1; Morie A. Gertz, MD5, Martha Q. Lacy MD5

Results A total of 25 patients have been accrued to the trial: 9 in phase I (3 at dose level 1 and 6 at dose level 2) 16 additional at dose level 2 for 22 total in phase II.

Results Phase I For the 9 patients in Phase I: Response in Phase I: Median age was 63 33% were mSMART intermediate or high risk Median number of prior regimens was 3 All patients had been treated with steroids and lenalidomide 89% had received and autologous stem cell transplant Response in Phase I: 8/9 pts responded (5CR, 2 VGPR and 1 PR)

Results – Phase II For the 16 patients at dose level 2: median age was 66, 31% percent had mSMART defined high risk status Median prior lines of therapy was 3 (1-6), 100% treated with lenalidomide, 75% had stem cell transplant 50% had bortezomib 31% received thalidomide Response rate is 94%: 5 CR, 4 VGPR and 6 PR.

Car-Pom-d

Car-Pom-d

Car-Pom-d

Car-Pom-d

Car-Pom-d

Car-Pom-d

Summary Combinatorial strategies probably best Unprecedented ability to induce response Good DOR Much more progress is needed!